TAMDEFLO REPORT AT TAM TRI DONG THAP GENERAL HOSPITAL

On June 10, 2026, Medbolide Pharmaceutical JSC participated in a scientific seminar organized by Tam Tri Dong Thap General Hospital. The event was attended by more than 50 doctors and medical staff from the hospital and was chaired by Dr. Chau Minh Tri, a Board-Certified Specialist (Level II) and the hospital’s Medical Director.

A company representative presented recommendations and clinical studies demonstrating the superior benefits of Deflazacort, a new-generation corticosteroid with potent anti-inflammatory effects and a higher safety profile compared to older-generation corticosteroids.

Following the presentation, the doctors discussed and expressed interest in Tamdeflo 6 (Deflazacort 6 mg), a more effective and clinically safer option for patients requiring corticosteroid treatment.

At the conclusion of the presentation, Medbolide expressed its gratitude and hope to continue partnering with Tam Tri Dong Thap General Hospital in providing solutions that improve patients’ quality of life.